All In Biotech

Drug Trial Radar · NCT06887127

A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis

An Open-label, Long-term Extension Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of TLL-018 in Patients With Rheumatoid Arthritis

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

350

Planned (sponsor's estimate)

Start

Mar 10, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Mar 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the long-term safety, tolerability, and efficacy of TLL-018 in patients with rheumatoid arthritis (RA) who have completed a preceding randomized controlled trial with TLL-018.

Conditions

  • Rheumatoid Arthritis

Interventions

  • TLL-018Drug

    TLL-018 20 mg BID for 78 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of occurrences and Percentage of Participants with AEs and SAEsTime frame: At Weeks 6, 12, 24, 36, 48, 60, 72, 78

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.